AACR News: Rigosertib Phase 1 results lead to disease-focused Phase 2 development
April 9, 2013 · Comments Off
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ.
Clinical trial hits new target in war on breast cancer
December 3, 2012 · Comments Off
KEY POINTS: In addition to estrogen, progesterone and HER2, androgen drives breast cancer The drug...
Enzalutamide adds five months survival in late-stage prostate cancer
August 16, 2012 · Comments Off
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the...
New clinical trial design promises to accelerate cancer drug approvals
June 12, 2012 · Comments Off
KEY POINTS: Cancer drug development can cost millions and take years New FDA regulations based...
Phase I study of rigosertib hits solid tumors two ways
June 3, 2012 · Comments Off
In IV form, the drug rigosertib is in a variety of current clinical trials, including...
Drug combination nearly doubles survival for subset of advanced non-small cell lung cancer patients
April 26, 2012 · Comments Off
THREE KEY POINTS: Results of 30-center phase II clinical trial show that combination of erlotinib...
ESCAPE trial hopes to find first major advance in treatment of small-cell lung cancer in over a decade
December 7, 2011 · Comments Off
A quarter of the approximately 30,000 people diagnosed with small cell lung cancer each year...
Colorado veterans with cancer will have better access to clinical trials thanks to a unique...
NTRK1: a new oncogene and target in lung cancer
December 6, 2011
ALK alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship cell signaling clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
Today is the day! Enjoy some blueberry pancakes and dress in all blue for Dress in Blue day to increase... http://t.co/LnYh9iT1lW
One last reminder. Wear blue tomorrow for Dress in Blue Day! http://t.co/dNKEDueKNv
In Health Care, Choice Is Overrated. We're glad our patient got the second opinion needed. Hope others can too. http://t.co/3T9CrAj8E2
President Obama has declared March National Colorectal Cancer Awareness Month! Remember to wear blue this Friday... http://t.co/neqgyKCzAC